CINC News and Press, CinCor Pharma Inc. From 09/27/22

SAN FRANCISCO and BOSTON, Sept. 27, 2022 (GLOBE NEWSWIRE) -- 5AM Ventures, a bicoastal venture capital firm, continues to attract preeminent talent as it celebrates 20 years of investing in early-stage life science companies. The firm is currently deploying capital in breakthrough science o...

WALTHAM, Mass., Aug. 31, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the following investor conferences: Citi's 17 th Annual BioPharma Conference taking place September 6 - 8, 2022 in Boston, MA and Morgan Stanl...

WALTHAM, Mass., Aug. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that the company will present Phase 1 clinical data on lead candidate baxdrostat as part of a poster presentation at the upcoming European Society of Cardiology (ESC) Congress taking place A...

WALTHAM, Mass., Aug. 15, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases, today a...

CinCor Pharma ( NASDAQ: CINC ) priced its underwritten public offering which was upsized to 7.5M shares and pre-funded warrants from the original offering size of 6M shares and pre-funded warrants. The offering consists of 4.9M shares , pre-funded warrants to purchase...

WALTHAM, Mass., Aug. 11, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases, today a...

CinCor Pharma ( NASDAQ: CINC ) on Monday announced an underwritten public offering of 6M shares . CINC may, in lieu of stock, offer and sell to certain investors pre-funded warrants to buy shares in the offering. The firm intends to grant underwriters a 30-day opt...

WALTHAM, Mass., Aug. 08, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (“CinCor”) (Nasdaq: CINC), a clinical-stage biopharmaceutical company focused on developing its lead clinical candidate, baxdrostat, for the treatment of hypertension and other cardio-renal diseases, today a...

Gainers: CinCor Pharma CINC +66% . Karuna Therapeutics KRTX +61% . 23andMe ( ME ) +22% . Cerevel Therapeutics ( CERE ) +20% . Quoin Pharmaceuticals ( QNRX ) +16% . Losers: Reata Pharmaceuticals RETA -31% . uniQure QUR...

CinCor Pharma press release ( NASDAQ: CINC ): Q2 GAAP EPS of -$0.56 misses by $0.08 . Cash, cash equivalents and marketable securities totaled $294.3 million as of June 30, 2022, as compared to $136.6 million as of December 31, 2021. Shares +28% PM For fu...